Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1–3) and other prooncogenic and prooncogenic receptor...

Full description

Bibliographic Details
Main Authors: Tohyama, Osamu, Matsui, Junji, Kodama, Kotaro, Hata-Sugi, Naoko, Kimura, Takayuki, Okamoto, Kiyoshi, Minoshima, Yukinori, Iwata, Masao, Funahashi, Yasuhiro
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177084/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177084/

Similar Items